This study is testing the long-term safety of a drug called fostamatinib disodium for people with warm antibody autoimmune hemolytic anemia (wAIHA). wAIHA is a condition where your body's immune system mistakenly attacks and destroys your red blood cells. Fostamatinib disodium comes in 100 mg and 150 mg doses. The study aims to see how safe fostamatinib is over time by tracking side effects, blood pressure, and a type of white blood cell called Absolute Neutrophil Count (ANC) for up to 104 weeks. You can join if you are 18 to 100 years old and have already completed 24 weeks of a previous study (C-935788-057) with this drug. The study plans to enroll 90 participants, but its current status is unclear.

Study design

This is an open-label study, meaning you and your doctors will know you are receiving fostamatinib disodium. It plans to include 90 participants.

What's involved

To join, you must have completed 24 weeks of a previous study (C-935788-057). The study will track your safety for up to 104 weeks.

Compensation

Not stated in the trial record.

Follow-up

Your safety will be followed for up to 104 weeks, measuring adverse events, blood pressure, and Absolute Neutrophil Count (ANC).

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.